Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

EMA reviewing pioglitazone safety

The European Medicines Agency (EMA) has announced (PDF) that it is conducting a safety review of pioglitazone containing medicines. The Food and Drugs Administration (FDA) is conducting a similar review.

This review is being conducted as a result of a recently completed French study which found an increased risk of bladder cancer. The French authorities have suspended the product license as a result of this finding pending a full review.

The results of the review are expected to be available in July. The EMA also state that the association between bladder cancer and pioglitazone use has been under continuous review since the product license was granted in 2000. Three previous reviews have failed to confirm a clear association but have indicated a potential increased risk in those with longest exposure and highest cumulative dose.

Action: Clinicians should be aware of this review. It would be prudent to avoid initiating new treatment with pioglitazone until the review is completed. Patients currently taking pioglitazone who are concerned about the potential increase in risk could be reviewed and have their treatment changed if this will maintain patient-clinician trust.

Share 'EMA reviewing pioglitazone safety' on Email Share 'EMA reviewing pioglitazone safety' on Delicious Share 'EMA reviewing pioglitazone safety' on Digg Share 'EMA reviewing pioglitazone safety' on Facebook Share 'EMA reviewing pioglitazone safety' on Google+ Share 'EMA reviewing pioglitazone safety' on reddit Share 'EMA reviewing pioglitazone safety' on StumbleUpon Share 'EMA reviewing pioglitazone safety' on Twitter

atomic-wealth

One Comments to “EMA reviewing pioglitazone safety”

  1. This is an interesting piece! Actos is a terrible drug that should be banned in the United States. This is because, it causes bladder cancer and other serious side effects. This is a great resource:

    http://www.weitzlux.com/actos-cancer_1962929.html

    Comment by Chris Jackson — July 15, 2011 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,209 spam comments.

atomic-wealth
fond-illness
summer